Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 747-759, December 2007

Role of autologous stem-cell transplantation in multiple myeloma

  • Michel Attal, MD (Professor of Hematology and Head of Hematology Department)
  • Jean-Luc Harousseau, MD (Professor of Hematology and Head of Hematology Department)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 2 40 08 32 71; Fax: +33 2 40 08 32 50.

Centre Hospitalier de Purpan, Place du Dr Baylac, 31059 Toulouse, France

Centre Hospitalier Universitaire Hôtel-Dieu, Place Alexis Ricordeau, 44093 Nantes Cedex 01, France

Multiple myeloma (MM) is one of the diseases in which the impact of dose intensity has been demonstrated. Consequently, in 2005MM was the first disease for which autologous stem-cell transplantation (ASCT) was indicated in Europe and the US. However, ASCT is not curative, and most patients relapse in a median of 3 years. The introduction of novel agents such as thalidomide, bortezomib (Velcade®) or lenalidomide (Revlimid®) was logical to try to improve the high-dose strategy, and promising results have been reported. This article will focus on the current results of ASCT and will discuss the main research area to try to improve this strategy.

Key words: multiple myeloma, high-dose therapy, autologous stem-cell transplantation, double transplantation, novel agents, thalidomide, bortezomib, lenalidomide, induction, maintenance

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(07)00072-2

doi:10.1016/j.beha.2007.09.006

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 747-759, December 2007

Article Tools